secwatch.observer — SEC 8-K summary
======================================

Issuer:     Estrella Immunopharma, Inc. (ESLA)
CIK:        0001844417
Form:       8-K
Filed at:   2025-12-04T23:59:59+00:00
Accession:  0001213900-25-118097
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Estrella advances STARLIGHT-1 to Phase II after DSMB OK; 100% CR in high-dose cohort
--------------------------------------------------------------------------------

- DSMB recommends Phase II at RP2D after no treatment-related SAEs in Phase I (n=9).
- High-dose cohort achieved 100% complete response (CR) rate at Month 1 in evaluable patients.
- Phase II expansion will evaluate EB103 in relapsed/refractory B-cell NHL at RP2D.
- Majority of Phase I patients were high-risk, including one with CNS lymphoma.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1844417/000121390025118097/0001213900-25-118097-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1844417/000121390025118097/ea0268496-8k_estrella.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-118097

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer